Ascletis's daily acne tablet set for China review after Phase III win

By Yahoo! Finance   |   1 month ago
Ascletis's daily acne tablet set for China review after Phase III win

Sagimet Bioscience's acne treatment, denifanstat, has shown success in a Phase III trial led by Ascletis Bioscience in China. The drug demonstrated efficacy in reducing skin lesions and inflammatory lesions with a good safety profile.

Read More

Did you find this insightful?